secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001689375-23-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada selects clinical candidate ENTR-601-45 for DMD exon 45 skipping; IND in H2 2024
--------------------------------------------------------------------------------

- ENTR-601-45 is an EEV-conjugated PMO targeting Duchenne patients amenable to exon 45 skipping.
- In vivo data showed >90% exon skipping in skeletal muscle of hDMD mouse model after single IV dose.
- More than 1,300 patients in US and Europe are exon 45 skipping amenable, per Entrada.
- Company plans to submit IND application in second half of 2024.
- Additional data expected at MDA Clinical & Scientific Conference in March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000003/0001689375-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937523000003/trda-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001689375-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer